Log In
BCIQ
Print this Print this
 

NanoActive nanoformulation of an angiotensin II receptor antagonist

  Manage Alerts
Collapse Summary General Information
Company NanGenex Inc.
DescriptionAngiotensin II receptor antagonist reformulated with NanGenex's NanoActive continuous flow technology platform
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard IndicationHypertension
Indication DetailsTreat hypertension
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today